Imperial College London
Portrait Picture

Dr Paul Turner

Faculty of Medicine, National Heart & Lung Institute

Reader in Paediatric Allergy & Clinical Immunology
 
 
 
//

Contact

 

+44 (0)20 3312 7754p.turner

 
 
//

Location

 

Children's Clinical Research FacilityCambridge WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Turner:2022:10.1016/j.jaip.2021.08.008,
author = {Turner, PJ and Patel, N and Ballmer-Weber, BK and Baumert, JL and Blom, WM and Brooke-Taylor, S and Brough, H and Campbell, DE and Chen, H and Chinthrajah, RS and Crevel, RWR and Dubois, AEJ and Ebisawa, M and Elizur, A and Gerdts, JD and Gowland, MH and Houben, GF and Hourihane, JOB and Knulst, AC and La, Vieille S and López, MC and Mills, ENC and Polenta, GA and Purington, N and Said, M and Sampson, HA and Schnadt, S and Södergren, E and Taylor, SL and Remington, BC},
doi = {10.1016/j.jaip.2021.08.008},
journal = {Journal of Allergy and Clinical Immunology: In Practice},
pages = {59--70},
title = {Peanut can be used as a reference allergen for hazard characterization in food allergen risk management: A rapid evidence assessment and meta-analysis},
url = {http://dx.doi.org/10.1016/j.jaip.2021.08.008},
volume = {10},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Regional and national legislation mandates the disclosure of “priority” allergens when present as an ingredient in foods, but this does not extend to the unintended presence of allergens due to shared production facilities. This has resulted in a proliferation of precautionary allergen (“may contain”) labels (PAL) which are frequently ignored by food allergic consumers. Attempts have been made to improve allergen risk management to better inform the use of PAL, but a lack of consensus has led to variety of regulatory approaches and non-uniformity in the use of PAL by food businesses. One potential solution would be to establish internationally-agreed “reference doses”, below which no PAL would be needed. However, if reference doses are to be used to inform the need for PAL, then it is essential to characterize the hazard associated with these low-level exposures. For peanut, there are now published data relating to over 3000 double-blind, placebo-controlled challenges in allergic individuals, but a similar level of evidence is lacking for other priority allergens. We present the results of a rapid evidence assessment and meta-analysis for the risk of anaphylaxis to low-level allergen exposure for priority allergens. On the basis of this analysis, we propose that peanut can and should be considered an exemplar allergen for the hazard characterization at low-level allergen exposure.
AU  - Turner,PJ
AU  - Patel,N
AU  - Ballmer-Weber,BK
AU  - Baumert,JL
AU  - Blom,WM
AU  - Brooke-Taylor,S
AU  - Brough,H
AU  - Campbell,DE
AU  - Chen,H
AU  - Chinthrajah,RS
AU  - Crevel,RWR
AU  - Dubois,AEJ
AU  - Ebisawa,M
AU  - Elizur,A
AU  - Gerdts,JD
AU  - Gowland,MH
AU  - Houben,GF
AU  - Hourihane,JOB
AU  - Knulst,AC
AU  - La,Vieille S
AU  - López,MC
AU  - Mills,ENC
AU  - Polenta,GA
AU  - Purington,N
AU  - Said,M
AU  - Sampson,HA
AU  - Schnadt,S
AU  - Södergren,E
AU  - Taylor,SL
AU  - Remington,BC
DO  - 10.1016/j.jaip.2021.08.008
EP  - 70
PY  - 2022///
SN  - 2213-2198
SP  - 59
TI  - Peanut can be used as a reference allergen for hazard characterization in food allergen risk management: A rapid evidence assessment and meta-analysis
T2  - Journal of Allergy and Clinical Immunology: In Practice
UR  - http://dx.doi.org/10.1016/j.jaip.2021.08.008
UR  - http://hdl.handle.net/10044/1/91024
VL  - 10
ER  -
Download